Stocktoria
Invivyd, Inc. IVVD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-08-06
Invivyd, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -104.0% | -696.8% | — | — | — |
| Net margin | -98.2% | -669.4% | — | — | — |
| FCF margin | -109.1% | -672.2% | — | — | — |
| Return on assets | -19.0% | -131.2% | -86.7% | -63.0% | -36.6% |
| Return on equity | -21.7% | -251.6% | -111.9% | -67.8% | -40.6% |
| Current ratio | 7.24 | 1.62 | 4.47 | 15.06 | 9.94 |
| Revenue growth | 110.5% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001832038 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.